Exhalation of 131I after radioiodine therapy: Dosimetric considerations based on measurements in exhaled air

被引:1
作者
Sudbrock, F. [1 ]
Fischer, Th. [1 ]
Zimmermanns, B. [1 ]
Drzezga, A. [1 ]
Schomaecker, K. [1 ]
机构
[1] Univ Hosp Cologne, Dept Nucl Med, D-50924 Cologne, Germany
关键词
Radioiodine therapy; Exhalation of radioactivity; Dosimetry; RADIATION-EXPOSURE; THYROID-DISEASES; FAMILIES; HYPERTHYROIDISM; INHALATION;
D O I
10.1016/j.jenvrad.2016.06.024
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
It is well known that a considerable amount of radioiodine is exhaled after radioiodine therapy (RIT) leading to unwanted radiation exposure through inhalation for non-involved persons. This study focuses on the amount of exhalation in the breath-out air of RIT-patients and the dosimetric consequences. Furthermore, the correlation between radioiodine uptake and exhalation was investigated. The radioiodine species were collected in a filter system and quantified over time by measurements with a scintillation counter. The dosimetric implications were then studied for different exposure scenarios. Of the activity administered to the patient, approximately 10(-3)% (50-110 ppm) is exhaled. The radioiodine inhalation taking place following exhalation in the vicinity yields doses of up to 500 mu Sv (children, staying with the patient immediately after application and for the next 8 h). Three days after administration the doses are significantly reduced. This study lays emphasis on previous assumptions that exhalation depends on thyroid storage. Regardless of the type of thyroid disease, the predominant form exhaled is organic radioiodine. The amount of exhaled radioiodine is small but from the point of view of radiation protection, by no means negligible immediately after administration. Radiation doses received by incqrporation of exhaled radioiodine can easily exceed 100 mu Sv soon after administration of radioiodine. Three days after RIT the radioactivity can still be measured in the exhaled air but even at maximum, the annual doses lie far below 10 mu Sv and are thus comparatively low. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 50 条
  • [41] Nationwide Survey on Implementation of 2011 Nuclear Regulatory Commission Policy on Release of Patients After 131I Therapy for Thyroid Cancer
    Wu, Di
    Lima, Cristiane J. Gomes
    Bloom, Gary
    Burman, Kenneth D.
    Wartofsky, Leonard
    Van Nostrand, Douglas
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (03) : 397 - 404
  • [42] BRAF V600E mutation in papillary thyroid cancer and its effect on postoperative radioiodine (131I) therapy: Should we modify our therapeutic strategy?
    Dominguez Ayala, Maite
    Exposito Rodriguez, Amaia
    Bilbao Gonzalez, Amaia
    Minguez Gabina, Pablo
    Gutierrez Rodriguez, Teresa
    Rodeno Ortiz de Zarate, Emilia
    Garcia Carrillo, Maitane
    Barrios Trevino, Borja
    [J]. CIRUGIA ESPANOLA, 2018, 96 (05): : 276 - 282
  • [43] The prevalence of thyroglossal tract thyroid tissue on SPECT/CT following 131I ablation therapy after total thyroidectomy for thyroid cancer
    Barber, Thomas W.
    Cherk, Martin H.
    Topliss, Duncan J.
    Serpell, Jonathan W.
    Yap, Kenneth S. K.
    Bailey, Michael
    Kalff, Victor
    [J]. CLINICAL ENDOCRINOLOGY, 2014, 81 (02) : 266 - 270
  • [44] Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders: real life experience and predictive factors of functional response
    Racaru, Lavinia Vija
    Fontan, Charlotte
    Bauriaud-Mallet, Mathilde
    Brillouet, Severine
    Caselles, Olivier
    Zerdoud, Slimane
    Bastie, Delphine
    Vallot, Delphine
    Caron, Philippe
    Bardies, Manuel
    Courbon, Frederic
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2017, 38 (09) : 756 - 763
  • [45] A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy:: a speculative paper
    Traino, Antonio C.
    Di Martino, Fabio
    Grosso, Mariano
    Monzani, Fabio
    Dardano, Angela
    Caraccio, Nadia
    Mariani, Giuliano
    Lazzeri, Mauro
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2006, 27 (05) : 439 - 446
  • [46] Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
    Plyku, Donika
    Hobbs, Robert F.
    Huang, Kevin
    Atkins, Frank
    Garcia, Carlos
    Sgouros, George
    Van Nostrand, Douglas
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (07) : 1146 - 1154
  • [47] High Failure Rates After 131I Therapy in Graves Hyperthyroidism Patients With Large Thyroid Volumes, High Iodine Uptake, and High Iodine Turnover
    de Jong, Jeroen A. F.
    Verkooijen, Helena M.
    Valk, Gerlof D.
    Zelissen, Pierre M. J.
    de Keizer, Bart
    [J]. CLINICAL NUCLEAR MEDICINE, 2013, 38 (06) : 401 - 406
  • [48] Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level
    Haenscheid, Heribert
    Verburg, Frederik Anton
    Biko, Johannes
    Diessl, Stefanie
    Demidchik, Yuri E.
    Drozd, Valentina
    Reiners, Christoph
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (07) : 1296 - 1302
  • [49] Prognostic Impact of Direct 131I Therapy After Detection of Biochemical Recurrence in Intermediate or High-Risk Differentiated Thyroid Cancer: A Retrospective Cohort Study
    Carrillo, Jose F.
    Vazquez-Romo, Rafael
    Ramirez-Ortega, Margarita C.
    Carrillo, Liliana C.
    Gomez-Argumosa, Edgar
    Onate-Ocana, Luis F.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [50] Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery
    Mueller, Andrea M.
    Schmohl, Kathrin A.
    Knoop, Kerstin
    Schug, Christina
    Urnauer, Sarah
    Hagenhoff, Anna
    Clevert, Dirk-Andre
    Ingrisch, Michael
    Niess, Hanno
    Carlsen, Janette
    Zach, Christian
    Wagner, Ernst
    Bartenstein, Peter
    Nelson, Peter J.
    Spitzweg, Christine
    [J]. ONCOTARGET, 2016, 7 (34) : 54795 - 54810